A detailed history of Mitsubishi Ufj Kokusai Asset Management Co., Ltd. transactions in Legend Biotech Corp stock. As of the latest transaction made, Mitsubishi Ufj Kokusai Asset Management Co., Ltd. holds 54,824 shares of LEGN stock, worth $2.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
54,824
Previous 55,402 1.04%
Holding current value
$2.33 Million
Previous $2.45 Million 8.89%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$43.55 - $59.88 $25,171 - $34,610
-578 Reduced 1.04%
54,824 $2.67 Million
Q2 2024

Aug 12, 2024

BUY
$39.5 - $57.22 $111,311 - $161,245
2,818 Added 5.36%
55,402 $2.45 Million
Q1 2024

May 09, 2024

BUY
$55.06 - $69.99 $502,257 - $638,448
9,122 Added 20.99%
52,584 $2.95 Million
Q4 2023

Feb 08, 2024

BUY
$57.25 - $69.74 $406,074 - $494,665
7,093 Added 19.5%
43,462 $2.62 Million
Q3 2023

Nov 07, 2023

BUY
$63.16 - $76.5 $318,326 - $385,560
5,040 Added 16.09%
36,369 $2.44 Million
Q2 2023

Aug 09, 2023

SELL
$46.28 - $75.01 $69,234 - $112,214
-1,496 Reduced 4.56%
31,329 $2.16 Million
Q1 2023

May 08, 2023

BUY
$43.42 - $57.37 $323,001 - $426,775
7,439 Added 29.3%
32,825 $1.58 Million
Q4 2022

Feb 07, 2023

SELL
$38.8 - $55.46 $38,450 - $54,960
-991 Reduced 3.76%
25,386 $1.27 Million
Q3 2022

Nov 01, 2022

BUY
$38.15 - $57.1 $4,616 - $6,909
121 Added 0.46%
26,377 $1.08 Million
Q2 2022

Aug 04, 2022

BUY
$33.54 - $55.0 $12,979 - $21,285
387 Added 1.5%
26,256 $1.44 Million
Q1 2022

May 09, 2022

BUY
$31.02 - $48.18 $351,332 - $545,686
11,326 Added 77.88%
25,869 $940,000
Q4 2021

Feb 07, 2022

BUY
$41.14 - $56.98 $248,814 - $344,615
6,048 Added 71.19%
14,543 $701,000
Q2 2021

Aug 06, 2021

BUY
$25.8 - $41.09 $219,171 - $349,059
8,495 New
8,495 $349,000

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $7.13B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Mitsubishi Ufj Kokusai Asset Management Co., Ltd. Portfolio

Follow Mitsubishi Ufj Kokusai Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Kokusai Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Kokusai Asset Management Co., Ltd. with notifications on news.